BACKGROUND: Cue-induced craving plays an important role in relapse, and the neural correlates of cue-induced craving have been elucidated using fMRI. This study examined the utility of real-time fMRI (rtfMRI) neurofeedback to strengthen self-regulation of craving-related neural activation and cue-reactivity in cigarette smokers. METHODS:Nicotine-dependent smokers were randomized to rtfMRI neurofeedback or to a no-feedback control group. Participants completed 3 neuroimaging visits. Within each visit, an initial run during which smoking-related cues were used to provoke craving, an individualized craving-related region of interest (ROI) in the prefrontal cortex or anterior cingulate cortex was identified. In the rtfMRI group, activity from the ROI was fed back via a visual display during 3 subsequent runs while participants were instructed to reduce craving during cue exposure. The control group had an identical experience with no feedback provided. RESULTS:Forty-four nicotine-dependent smokers were recruited to participate in our study; data from the 33 participants who completed a 1-week follow-up visit were included in the analysis. Subjective craving ratings and cue-induced brain activation were lower in the rtfMRI group than in the control group. LIMITATIONS: As participants were not seeking treatment, clinical outcomes are lacking. CONCLUSION:Nicotine-dependent smokers receiving rtfMRI feedback from an individualized ROI attenuated smoking cue-elicited neural activation and craving, relative to a control group. Further studies are needed in treatment-seeking smokers to determine if this intervention can translate into a clinically meaningful treatment modality.
RCT Entities:
BACKGROUND: Cue-induced craving plays an important role in relapse, and the neural correlates of cue-induced craving have been elucidated using fMRI. This study examined the utility of real-time fMRI (rtfMRI) neurofeedback to strengthen self-regulation of craving-related neural activation and cue-reactivity in cigarette smokers. METHODS:Nicotine-dependent smokers were randomized to rtfMRI neurofeedback or to a no-feedback control group. Participants completed 3 neuroimaging visits. Within each visit, an initial run during which smoking-related cues were used to provoke craving, an individualized craving-related region of interest (ROI) in the prefrontal cortex or anterior cingulate cortex was identified. In the rtfMRI group, activity from the ROI was fed back via a visual display during 3 subsequent runs while participants were instructed to reduce craving during cue exposure. The control group had an identical experience with no feedback provided. RESULTS: Forty-four nicotine-dependent smokers were recruited to participate in our study; data from the 33 participants who completed a 1-week follow-up visit were included in the analysis. Subjective craving ratings and cue-induced brain activation were lower in the rtfMRI group than in the control group. LIMITATIONS: As participants were not seeking treatment, clinical outcomes are lacking. CONCLUSION:Nicotine-dependent smokers receiving rtfMRI feedback from an individualized ROI attenuated smoking cue-elicited neural activation and craving, relative to a control group. Further studies are needed in treatment-seeking smokers to determine if this intervention can translate into a clinically meaningful treatment modality.
Authors: David E J Linden; Isabelle Habes; Stephen J Johnston; Stefanie Linden; Ranjit Tatineni; Leena Subramanian; Bettina Sorger; David Healy; Rainer Goebel Journal: PLoS One Date: 2012-06-04 Impact factor: 3.240
Authors: Kymberly D Young; Greg J Siegle; Vadim Zotev; Raquel Phillips; Masaya Misaki; Han Yuan; Wayne C Drevets; Jerzy Bodurka Journal: Am J Psychiatry Date: 2017-04-14 Impact factor: 18.112
Authors: Xingbao Li; Lian Du; Gregory L Sahlem; Bashar W Badran; Scott Henderson; Mark S George Journal: Drug Alcohol Depend Date: 2017-02-28 Impact factor: 4.492
Authors: Elizabeth A Cabrera; Corinde E Wiers; Elsa Lindgren; Gregg Miller; Nora D Volkow; Gene-Jack Wang Journal: J Neuroimmune Pharmacol Date: 2016-05-16 Impact factor: 4.147
Authors: Bettina Sorger; Frank Scharnowski; David E J Linden; Michelle Hampson; Kymberly D Young Journal: Neuroimage Date: 2018-11-10 Impact factor: 6.556
Authors: David W Frank; Paul M Cinciripini; Menton M Deweese; Maher Karam-Hage; George Kypriotakis; Caryn Lerman; Jason D Robinson; Rachel F Tyndale; Damon J Vidrine; Francesco Versace Journal: Nicotine Tob Res Date: 2020-07-16 Impact factor: 4.244
Authors: Hestia Moningka; Sarah Lichenstein; Patrick D Worhunsky; Elise E DeVito; Dustin Scheinost; Sarah W Yip Journal: Neuropsychopharmacology Date: 2018-10-03 Impact factor: 7.853